IR-Med Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IRME research report →
Price Chart
About the company
IR-Med Inc. is an emerging medical technology firm dedicated to developing advanced diagnostic and medical solutions by leveraging a platform that integrates infra-red light spectroscopy with artificial intelligence. The company's product pipeline includes PressureSafe, a handheld optical monitoring device engineered for the early identification of pressure-induced tissue damage in the skin and subcutaneous layers, often resulting from extended periods of patient immobility.
- CEO
- Oded Bashan
- IPO
- 2021
- Employees
- 3
- HQ
- Rosh Pinna, HZ, IL
Get TickerSpark's AI analysis on IRME
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $162.20K
- P/E
- -0.10
- Fwd P/E
- 0.01
- PEG
- -0.00
- P/S
- 0.00
- P/B
- -0.25
- EV/EBITDA
- -0.66
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 263.69%
- ROIC
- 143.73%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-21,000-23.5%
- Op Income
- $-1,941,000
- Net Income
- $-1,899,000+61.3%
- EPS
- $-0.03+62.0%
- OCF Growth
- +57.1%
- FCF Growth
- +57.1%
- 52W High
- $0.05
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.01
- Beta
- 0.72
- RSI (14)
- 24
- Avg Volume
- 98
No earnings-call transcripts are available for IRME yet.
- Free Float
- 38.2%
- Shares Outstanding
- 77.24M
- Float Shares
- 29.48M
Our IRME coverage
Recent articles, reports, and earnings notes.
No research on IRME yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IRME report →IR-MED Ltd. Announces Launch of First-in-Human Clinical Trial of Its DiaSafe(TM) Device for Diabetic Foot Ulcer (DFU) Assessment
newsfilecorp.com · Nov 3
IR-MED's Key Clinical and Media Milestones
newsfilecorp.com · Oct 27
IR-MED Investor Update Letter - Sept-2025
newsfilecorp.com · Sep 16
IR-MED Reports Positive Interim Results from U.S. Clinical Study of PressureSafe(TM) for Pressure Injury Assessment Across Diverse Skin Tones
newsfilecorp.com · Jun 23
IR-MED Awarded $500,000 Grant from the Israel Innovation Authority to Advance AI-Powered DiaSafe(TM) Device for Diabetic Foot Ulcer Assessment
newsfilecorp.com · May 5
IR-MED CEO Issues Letter to Shareholders: Expanding Our Platform and Presenting New Clinical Data from Israel and the U.S.
globenewswire.com · Mar 18
Methodist Healthcare Adopts IR-MED's PressureSafe™ Device for Usability Study: Decision Support Device Aims to Reduce Substantial Healthcare Burden of Pressure Injuries
globenewswire.com · Sep 10
IR-MED Appoints Ran Ziskind, Tech Entrepreneur, Growth Manager, and Inventor as Chief Executive Officer
globenewswire.com · Aug 28
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.